CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-12-10
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor
(CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple
myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune
cells can be engineered to kill multiple myeloma cells by inserting a piece of
deoxyribonucleic acid (DNA) into the immune cells using a lentiviral vector such as CS1, that
allows them to recognize multiple myeloma cells. These engineered immune cells, CS1-CAR T
cells, may kill multiple myeloma cells.